Abstract
In a post hoc analysis of the Community-Acquired Pneumonia (CAP) immunization Trial in Adults the model-predicted 13-valent pneumococcal conjugate vaccine efficacy for preventing vaccine-type specific CAP and Invasive Pneumococcal Disease declined from 65% to 40% for subjects being 65 and 75 year olds at the time of vaccination, respectively.
| Original language | English |
|---|---|
| Pages (from-to) | 1835-1838 |
| Number of pages | 4 |
| Journal | Clinical Infectious Diseases |
| Volume | 61 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 15 Dec 2015 |
Keywords
- pneumococcal conjugate vaccine
- community-acquired pneumonia
- invasive pneumococcal disease
- vaccine efficacy
- immunosenescence
Fingerprint
Dive into the research topics of 'The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver